The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years or older receiving lower intensity treatment (LIT), including the adoption ...
A panelist discusses how a large propensity score–matched analysis of 1300 patients aged 60-75 found similar all-cause mortality between intensive chemotherapy and azacitidine plus venetoclax, but ...
Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL We retrospectively analyzed 473 adult patients with ...
The ASAP trial sets new perspectives on international therapy standards: High-dose chemotherapy is not always necessary before transplantation in cases of acute myeloid leukemia (AML). This means ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results